Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-05-23 Director's Dealing
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于公司部分高级管理人员自筹资金参与公司股权激励计划暨增持公司股票的公告
Director's Dealing Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding certain senior management personnel voluntarily using their own funds to participate in the company's equity incentive plan and increase their holdings of company stock. It details the number of shares increased, the price range, the personnel involved, and the impact on shareholding structure. The document is a formal announcement about insider share purchases related to equity incentives, not a financial report, earnings release, or regulatory filing about financial results. It fits the definition of 'Director's Dealing' as it reports personal share transactions by company directors and executives (insider trades). The document length is 1838 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2016-05-23 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It details the purpose, method, price range, funds used, shares repurchased, and impact analysis of a share buyback program by the company. It includes specific data on the number of shares repurchased, the price range, funding sources, and the effect on shareholding structure. This is a detailed report on the company's repurchase of its own shares, which fits the category of 'Transaction in Own Shares' (POS). The document length is under 5,000 characters but contains substantive details about the repurchase, not just an announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is POS with high confidence.
2016-05-20 Chinese
股权激励计划股份回购结果公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the results of a share repurchase related to its equity incentive plan. It details the number of shares repurchased, the price range, the total amount spent, and the status of the repurchased shares. The document does not contain financial statements or comprehensive financial data but focuses on the transaction of the company's own shares. This matches the definition of a 'Transaction in Own Shares' filing, which reports on share buybacks or sales by the company. The document length is short (1284 characters), and it is not an announcement of a report publication but a direct disclosure of a share repurchase event.
2016-05-20 Chinese
八届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details voting results on specific proposals, including a restricted stock incentive plan and a stock repurchase plan. The document is titled as a board resolution announcement and includes voting details and mentions of directors recusing themselves. It is not a full report, financial statement, or presentation, but rather an official announcement of board decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, not a full report or regulatory filing.
2016-05-13 Chinese
股权激励计划当期购买股份开始公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the start of a share repurchase related to an equity incentive plan. It details the purpose, basis, method, price, quantity, funding source, and expected impact of the share buyback. The document is not a financial report, earnings release, or management discussion, but rather a formal notice about the company's share repurchase activity. It does not contain financial statements or detailed financial analysis but focuses on the share repurchase plan and execution. Therefore, it fits the category of Transaction in Own Shares (POS), which covers announcements of company buying back its own shares.
2016-05-13 Chinese
限制性股票激励计划2015年度股权激励基金提取说明的专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is a special attestation report issued by a certified public accounting firm regarding the 2015 annual stock incentive fund extraction explanation of Kunming Pharmaceutical Group Co., Ltd. It includes the auditor's responsibilities, management's responsibilities, and an audit opinion on the stock incentive fund extraction explanation. The document is titled as a "专项鉴证报告" (special attestation report) and contains no full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a standalone audit-related report focusing on a specific aspect of the company's stock incentive plan fund extraction for 2015. The document length is about 3213 characters, which is relatively short and focused. It is not a mere announcement or certification letter but a detailed audit attestation report. Therefore, it fits best under the category of Audit Report / Information (AR).
2016-05-13 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.